DNA vaccine study backs electroporation technology:
This article was originally published in Clinica
Executive Summary
Animal trial results for Genetronics Biomedical's electroporation technique for enhancing the efficacy of DNA vaccines continue to show promise, the San Diego, California firm has reported. In a study performed in collaboration with Chiron, electroporation-enhanced DNA vaccination was found to provide faster, stronger, and longer-lasting antibody and cellular immune responses. Presented at this month's American Society of Gene Therapy meeting in Minneapolis, Minnesota, the results indicated that an electroporation regimen using Genetronics' technology provided antibody levels in rabbits equivalent to levels of more invasive, earlier-generation electroporation equipment, the company said.